Fractyl Health(GUTS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GUTS Fractyl Health

未开盘 07-31 16:00:00 EDT

0.6850

-0.0050

-0.72%

盘后0.6850

+0.00000.00%

19:59 EDT

最高0.7000	最低0.6722	成交量62.21万
今开0.6998	昨收0.6900	日振幅4.03%
总市值1.09亿	流通市值8,768万	总股本1.59亿
成交额42.99万	换手率0.49%	流通股本1.28亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GUTS","market":"US","secType":"STK","nameCN":"Fractyl Health","latestPrice":0.685,"timestamp":1785528000000,"preClose":0.69,"halted":0,"volume":622113,"hourTrading":{"tag":"盘后","latestPrice":0.685,"preClose":0.685,"latestTime":"19:59 EDT","volume":16080,"amount":11077.158231,"timestamp":1785542341951,"change":0,"changeRate":0,"amplitude":0.019854},"delay":0,"changeRate":-0.007246376811594049,"floatShares":128000000,"shares":158648963,"eps":-1.527,"marketStatus":"未开盘","change":-0.005,"latestTime":"07-31 16:00:00 EDT","open":0.6998,"high":0.7,"low":0.6722,"amount":429908.84950512,"amplitude":0.04029,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.527,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785744000000},"marketStatusCode":0,"adr":0,"listingDate":1706850000000,"exchange":"NASDAQ","adjPreClose":0.69,"preHourTrading":{"tag":"盘前","latestPrice":0.7,"preClose":0.69,"latestTime":"09:29 EDT","volume":12193,"amount":8594.8530158,"timestamp":1785504595557,"change":0.01,"changeRate":0.014493,"amplitude":0.086377},"postHourTrading":{"tag":"盘后","latestPrice":0.685,"preClose":0.685,"latestTime":"19:59 EDT","volume":16080,"amount":11077.158231,"timestamp":1785542341951,"change":0,"changeRate":0,"amplitude":0.019854},"volumeRatio":0.38286859766558773},"requestUrl":"/m/hq/s/GUTS/wiki","defaultTab":"wiki","newsList":[{"id":"1192789379","title":"Fractyl Health：关键六个月REMAIN-1数据预计2026年第四季度初出炉；FDA提交计划定于2026年第四季度末","url":"https://stock-news.laohu8.com/highlight/detail?id=1192789379","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192789379?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:07","pubTimestamp":1784110036,"startTime":"0","endTime":"0","summary":"Fractyl Health公司宣布，其关键性REMAIN-1研究的六个月主要疗效数据预计将在2026年第四季度初获得。紧随其后，公司计划于2026年第四季度末向美国食品药品监督管理局（FDA）提交监管申请。这一时间表标志着该公司在推进其创新疗法方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102280016","title":"Fractyl Health：未报告器械相关严重不良事件，各组间治疗期不良事件发生率相近","url":"https://stock-news.laohu8.com/highlight/detail?id=1102280016","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102280016?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:03","pubTimestamp":1784109826,"startTime":"0","endTime":"0","summary":"Fractyl Health 公布的数据显示，在其相关试验中，未报告与器械相关的严重不良事件。此外，各组间观察到的治疗期不良事件发生率也基本相似。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155921565","title":"Fractyl Health公布REMAIN-1中期队列随机数据：GLP-1停药一年后体重维持效果显著","url":"https://stock-news.laohu8.com/highlight/detail?id=1155921565","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155921565?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:03","pubTimestamp":1784109784,"startTime":"0","endTime":"0","summary":"Fractyl Health公布了其REMAIN-1研究中期队列的积极随机数据。数据显示，在接受该公司疗法后停止使用GLP-1受体激动剂的患者，在停药一年后仍成功维持了减重效果。\n这项数据凸显了该疗法在实现持久体重管理方面的潜力。当前，许多患者在停止使用GLP-1类药物后，体重容易出现反弹。REMAIN-1研究的中期结果为此挑战提供了一个潜在的解决方案。\n研究结果表明，该介入性疗法可能帮助患者长期维持健康体重，即使是在停止使用GLP-1药物之后。这为肥胖症的长期管理开辟了新的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137439656","title":"Fractyl Health公布Reveal-1开放标签研究积极一年期结果：单次Revita®手术后实现GLP-1停药后体重持续维持","url":"https://stock-news.laohu8.com/highlight/detail?id=1137439656","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137439656?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:03","pubTimestamp":1780571015,"startTime":"0","endTime":"0","summary":"Fractyl Health公司报告了其Reveal-1开放标签研究取得的积极一年期结果。数据显示，在接受单次Revita®手术后，患者在停止GLP-1药物治疗后，体重得以持续维持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177113082","title":"Fractyl Health宣布Rejuva临床开发项目资金已到位至2027年初，资本计划维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1177113082","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177113082?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:02","pubTimestamp":1778497350,"startTime":"0","endTime":"0","summary":"Fractyl Health公司宣布，其Rejuva临床开发项目已获得充足资金支持，足以持续至2027年初。公司目前的资本计划保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100914453","title":"Fractyl Health获准在荷兰启动Rjva-001首次人体试验：首个进入2型糖尿病临床开发阶段的基因疗法候选药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1100914453","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100914453?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:01","pubTimestamp":1778497309,"startTime":"0","endTime":"0","summary":"Fractyl Health已获得授权，将在荷兰启动其候选药物Rjva-001的首次人体临床试验。这标志着该药物成为全球首个进入针对2型糖尿病临床开发阶段的基因疗法候选产品。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170305837","title":"Fractyl Health将于2026年3月24日公布2025年第四季度及全年财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1170305837","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170305837?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:01","pubTimestamp":1773745279,"startTime":"0","endTime":"0","summary":"Fractyl Health计划于2026年3月24日发布2025财年第四季度及全年财务报告，届时将同步披露公司最新业务动态。此次公告将全面展示企业在财务表现和战略推进方面的关键成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142614142","title":"Fractyl Health完成Revita®用于GLP-1治疗后体重维持的REMAIN-1关键队列随机分组","url":"https://stock-news.laohu8.com/highlight/detail?id=1142614142","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142614142?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:03","pubTimestamp":1772107438,"startTime":"0","endTime":"0","summary":"Fractyl Health宣布，其针对GLP-1受体激动剂治疗后体重维持的Revita®疗法，已顺利完成REMAIN-1关键研究队列的随机化分组工作。这一里程碑标志着该创新代谢干预方案向临床验证迈出关键一步。\n随机化过程的完成，为评估Revita®在维持减肥效果方面的有效性与安全性奠定了坚实基础。研究结果有望为接受GLP-1治疗后面临体重反弹难题的患者提供全新解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612298478","title":"Fractyl Health, Inc.盘中异动 下午盘股价大涨5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612298478","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612298478?lang=zh_cn&edition=full","pubTime":"2026-02-19 04:12","pubTimestamp":1771445578,"startTime":"0","endTime":"0","summary":"北京时间2026年02月19日04时12分，Fractyl Health, Inc.股票出现异动，股价急速拉升5.30%。Fractyl Health, Inc.股票所在的生物技术行业中，整体跌幅为0.10%。其相关个股中，Sensei Biotherapeutics, Inc.、Cardio Diagnostics Holdings Inc.、Moolec Science Sa C/Wts 30/01/2028涨幅较大，Cardio Diagnostics Holdings Inc.、Moolec Science Sa、Sensei Biotherapeutics, Inc.较为活跃，换手率分别为2432.91%、953.51%、912.28%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Cardio Diagnostics Holdings Inc.、Sensei Biotherapeutics, Inc.，振幅分别为160.33%、137.65%、108.11%。Fractyl Health, Inc.公司简介：Fractyl Health Inc 是一家代谢治疗公司，专注于开发治疗代谢疾病的新方法，包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021904125895416b98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021904125895416b98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609739279","title":"Fractyl Health, Inc.盘中异动 快速下跌5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609739279","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609739279?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:11","pubTimestamp":1770217876,"startTime":"0","endTime":"0","summary":"北京时间2026年02月04日23时11分，Fractyl Health, Inc.股票出现波动，股价急速下跌5.61%。Fractyl Health, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Celularity Inc C/Wts 16/07/2026 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、阿诺医药涨幅较大，Biodexa Pharmaceuticals Plc、Gri Bio, Inc.、Evogene Ltd.较为活跃，换手率分别为380.93%、196.84%、116.84%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Liminatus Pharma, Inc.，振幅分别为61.25%、33.87%、33.64%。Fractyl Health, Inc.公司简介：Fractyl Health Inc 是一家代谢治疗公司，专注于开发治疗代谢疾病的新方法，包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204231117a47c6dd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204231117a47c6dd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607039539","title":"Fractyl Health, Inc.股价重挫66.81% 市值跌6222.88万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607039539","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607039539?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:41","pubTimestamp":1769697686,"startTime":"0","endTime":"0","summary":"北京时间2026年01月29日22时41分，Fractyl Health, Inc.股票出现异动，股价快速跳水66.81%。Fractyl Health, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。其相关个股中，Jasper Therapeutics Inc C/Wts 24/09/2026 、Briacell Therapeutics Corp C/Wts 、Serina Therapeutics, Inc.涨幅较大，Serina Therapeutics, Inc.、Aspire Biopharma Holdings, Inc.、Aprea Therapeutics, Inc.较为活跃，换手率分别为453.27%、103.55%、66.45%，振幅较大的相关个股有Biomx Inc.、Aprea Therapeutics, Inc.、Dermata Therapeutics, Inc.，振幅分别为31.00%、27.75%、21.83%。Fractyl Health, Inc.公司简介：Fractyl Health Inc 是一家代谢治疗公司，专注于开发治疗代谢疾病的新方法，包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129224126a4653e1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129224126a4653e1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102929804","title":"Fractyl Health股价暴跌64%；公司公布停用减肥药后体重反弹的早期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1102929804","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102929804?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:34","pubTimestamp":1769697277,"startTime":"0","endTime":"0","summary":"Fractyl Health股价今日大幅下挫64%，创下近期最大单日跌幅。该公司同期发布了关于患者停止使用其肥胖症药物后出现体重反弹现象的初步研究数据。\n这份早期数据显示，在终止药物治疗后，部分患者的体重出现了显著回升。这一发现引发市场对该公司核心产品长期疗效可持续性的担忧，可能直接影响其未来商业化前景。\n股价的剧烈波动反映出投资者对该数据的负面解读，同时也凸显了肥胖症治疗领域药物研发存在的高风险特性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171819577","title":"Fractyl Health 预计将于2026年第二季度获得FDA关于采用De Novo审批途径可能性的反馈","url":"https://stock-news.laohu8.com/highlight/detail?id=1171819577","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171819577?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:08","pubTimestamp":1769688510,"startTime":"0","endTime":"0","summary":"Fractyl Health Inc. 近日透露，公司预计将在2026年第二季度获得美国食品药品监督管理局（FDA）的关键反馈。此次沟通的核心议题是探讨其产品是否具备采用De Novo审批途径的资格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518400504","title":"Fractyl Health, Inc.2024财年实现净利润-68.69百万美元，同比增加10.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518400504","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518400504?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449682,"startTime":"0","endTime":"0","summary":"3月9日，Fractyl Health, Inc.公布财报，公告显示公司2024财年净利润为-68.69百万美元，同比增加10.90%；其中营业收入为93000.00美元，同比减少22.50%，每股基本收益为-1.44美元。从资产负债表来看，Fractyl Health, Inc.总负债79.65百万美元，其中短期债务4.96百万美元，资产负债比为0.02，流动比率为3.63。机构评级：截至2025年3月9日，当前有2家机构对Fractyl Health, Inc.目标价做出预测，其中目标均价为8.00美元，其中最低目标价为6.00美元，最高目标价为10.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000252a266b42b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000252a266b42b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517926161","title":"Fractyl Health, Inc.盘中异动 下午盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517926161","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517926161?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:22","pubTimestamp":1741206128,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时22分，Fractyl Health, Inc.股票出现异动，股价急速上涨5.00%。Fractyl Health, Inc.股票所在的生物技术行业中，整体涨幅为1.86%。其相关个股中，Chimerix, Inc.、Geovax Labs Inc C/Wts 29/09/2025、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为973.32%、318.27%、313.68%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Geovax Labs Inc C/Wts 29/09/2025，振幅分别为82.59%、54.27%、51.93%。Fractyl Health, Inc.公司简介：Fractyl Health Inc 是一家代谢治疗公司，专注于开发治疗代谢疾病的新方法，包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306042208abea129d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306042208abea129d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516669144","title":"Fractyl Health(GUTS.US)：2024年Q4财报实现营收3000美元，前值为7000美元，预期值为1万美元；每股收益为-0.52美元，前值为-11.18美元，预期值为-0.44美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516669144","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516669144?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:29","pubTimestamp":1741037354,"startTime":"0","endTime":"0","summary":"Fractyl Health(GUTS.US)：2024年Q4财报实现营收3000美元，前值为7000美元，预期值为1万美元；每股收益为-0.52美元，前值为-11.18美元，预期值为-0.44美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04052948499182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126943086","title":"Fractyl Health第四季度GAAP每股收益$(0.52)不及预期$(0.34)，销售额$3.00K不及预期$10.00K","url":"https://stock-news.laohu8.com/highlight/detail?id=1126943086","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126943086?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:20","pubTimestamp":1741036842,"startTime":"0","endTime":"0","summary":"Fractyl Health 公布的季度每股亏损为$，低于分析师普遍预期的$，差异为52.94%。与去年同期$7.00千美元的销售额相比，这一数据下降了57.14%。以上内容来自Benzinga Earnings专栏，原文如下：$Fractyl Health$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 52.94 percent. This is a 95.35 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $3.00 thousand which missed the analyst consensus estimate of $10.00 thousand by 70.00 percent.  This is a 57.14 percent decrea","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Fractyl Health第四季度GAAP每股收益$(0.52)不及预期$(0.34)，销售额$3.00K不及预期$10.00K","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516360637","title":"Fractyl Health, Inc.盘中异动 股价大跌5.13%报1.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516360637","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516360637?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:50","pubTimestamp":1741013423,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时50分，Fractyl Health, Inc.股票出现波动，股价大幅跳水5.13%。截至发稿，该股报1.48美元/股，成交量2.5566万股，换手率0.05%，振幅10.22%。Fractyl Health, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。Fractyl Health, Inc.公司简介：Fractyl Health Inc 是一家代谢治疗公司，专注于开发治疗代谢疾病的新方法，包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032250249637b1e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032250249637b1e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514380124","title":"Fractyl Health, Inc.盘中异动 临近午盘急速拉升5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514380124","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514380124?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:47","pubTimestamp":1740674836,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日00时47分，Fractyl Health, Inc.股票出现波动，股价急速拉升5.40%。Fractyl Health, Inc.股票所在的生物技术行业中，整体涨幅为0.43%。其相关个股中，Osr Holdings Inc C/Wts 09/02/2028 、Alpha Tau Medical Ltd C/Wts 、Pepgen Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1691.29%、276.32%、114.71%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Quoin Pharmaceuticals Ltd、Pds Biotechnology Corporation，振幅分别为86.14%、47.79%、45.45%。Fractyl Health, Inc.公司简介：Fractyl Health Inc 是一家代谢治疗公司，专注于开发治疗代谢疾病的新方法，包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228004717abdf8e99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228004717abdf8e99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512743100","title":"Fractyl Health, Inc.盘中异动 临近收盘股价大跌5.23%报1.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512743100","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512743100?lang=zh_cn&edition=full","pubTime":"2025-02-20 05:02","pubTimestamp":1739998935,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日05时02分，Fractyl Health, Inc.股票出现波动，股价急速下跌5.23%。截至发稿，该股报1.45美元/股，成交量24.9485万股，换手率0.52%，振幅6.89%。Fractyl Health, Inc.股票所在的生物技术行业中，整体涨幅为0.91%。Fractyl Health, Inc.公司简介：Fractyl Health Inc 是一家代谢治疗公司，专注于开发治疗代谢疾病的新方法，包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220050215a24c405b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220050215a24c405b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","GUTS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.fractyl.com","stockEarnings":[{"period":"1week","weight":-0.1138},{"period":"1month","weight":-0.1246},{"period":"3month","weight":-0.0204},{"period":"6month","weight":0.4891},{"period":"1year","weight":-0.6277},{"period":"ytd","weight":-0.6886}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0366},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.0955}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Fractyl Health, Inc.于2010年8月30日在特拉华州注册成立。该公司是一家临床阶段的代谢疗法公司，专注于开发治疗肥胖和2型糖尿病的新方法。其主要候选产品Revita DMR系统旨在重塑十二指肠黏膜，以解决代谢疾病的根本原因。","exchange":"NASDAQ","name":"Fractyl Health","nameEN":"Fractyl Health"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fractyl Health(GUTS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Fractyl Health(GUTS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Fractyl Health,GUTS,Fractyl Health股票,Fractyl Health股票老虎,Fractyl Health股票老虎国际,Fractyl Health行情,Fractyl Health股票行情,Fractyl Health股价,Fractyl Health股市,Fractyl Health股票价格,Fractyl Health股票交易,Fractyl Health股票购买,Fractyl Health股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fractyl Health(GUTS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Fractyl Health(GUTS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}